Clinical Trials Browser

Phase 3 × Triple Negative Breast Neoplasms × Epirubicin × Clear all

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05862064 2025-07-16

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT04296175 2025-03-26

CITRINE

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT03876886 2019-03-21

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

Phase 3 Unknown

Triple Negative Breast Neoplasms

NCT01378533 2011-12-28

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

Phase 3 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms